Russia deepening localization in domestic pharma market

12 February 2025

At least 90% of drugs from the list of vital medicines in Russia will be of domestic origin already by the end of 2025, according to latest predictions by some senior officials of the Russian Ministry of Health, reports The Pharma Letter’s local correspondent.

Currently, over 800 generic items and more than 5,000 trade named drugs that are available in the Russian market are positioned as “domestic drugs” in Russia. In May 2024, the Ministry reported that 80% of them are produced within the territory of the Russian Federation.

Still, this is just the beginning, while as part of state plans is to create conditions for deepening of the level of localization in the domestic pharmaceutical market. For this purpose, last summer the Russian government changed the rules for forming the list of vital drugs, providing a priority to Russian drugs or those whose production is localized within the territory of the country.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical